• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SLRX

SLRX

Salarius Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.84

+0.19 (+29.23%)

Company Profile

CEO

Frederick E. Pierce

IPO Date

2015-01-29

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.71

Prev. Close

$0.65

Day Low

$0.69

Day High

$0.90

52W Low

$0.52

52W High

$52.95

Market Cap

$0.00B

Volume

5.96M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

18.9%

Avg Negative

2.8%

Avg Neutral

78.2%

News Feed

Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results

GlobeNewsWire·7/29/2021·↓ negative

Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit

GlobeNewsWire·7/14/2021·↑ positive

Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

GlobeNewsWire·7/13/2021·↑ positive

Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

GlobeNewsWire·7/9/2021·↑ positive

REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

GlobeNewsWire·6/17/2021·↓ negative

Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat

Benzinga·6/15/2021·↑ positive

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

GlobeNewsWire·6/15/2021·↑ positive

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

GlobeNewsWire·6/10/2021·↓ negative

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat's Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

GlobeNewsWire·6/7/2021·↑ positive

Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

GlobeNewsWire·5/19/2021·↑ positive